Investigating the Prevention of Endometrial CAncer with Metformin (PECAM Study)- a study involving postmenopausal women with hormone receptor positive breast cancer who are currently on tamoxifen therapy for at least 6 weeks.

Monash University0 sites130 target enrollmentStarted: August 7, 2014Last updated: January 13, 2020

Conditions

Trial Snapshot

No summary available.

•Postmenopausal women, aged < 75 years, who are currently taking tamoxifen therapy for at least 6 weeks for treatment of hormone receptor positive breast cancer.

•1.Women who are premenopausal / perimenopausal / > 75 years old
•2.Women with advanced breast cancer and likely to have progression of their disease within the study period, as assessed by their treating oncologist.
•3.Women with any of the following on screening:
•a)Use of any systemic hormones in the last 6 months;
•b) serious endocrine disorder with systemic disease;
•c) alcohol consumption greater than 3 standard drinks per day;
•d) known acute or chronic renal, liver disease or cardiovascular disease;
•e) insulin dependent diabetes mellitus or use of an oral hypoglycemic agent;
•4. <6 months amenorrhoea so that the likelihood of ovulatory cycles during the study will be small.
•5. EH with atypia or ECa on endometrial biopsy or hysteroscopy and curettage.
•6. Women who, in the opinion of the investigator, are a poor medical or psychiatric risk for treatment in a research protocol.

Sponsor